TEL AVIV, November 20, 2025 — Leads & Copy — Nasus Pharma Ltd. (NYSE: NSRX) has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer.
Mr. Rubin brings over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries to the company. He will be responsible for overseeing Nasus Pharma’s financial operations, including corporate finance, financial planning, capital strategy, and investor relations.
According to Dan Teleman, Chief Executive Officer of Nasus Pharma, Mr. Rubin’s deep financial expertise and track record make him the ideal addition to the leadership team as the company enters an important phase of growth.
Udi Gilboa, Executive Chairman of Nasus Pharma, stated that Mr. Rubin’s experience in both emerging biotechnology companies and commercial-stage pharmaceutical organizations will be valuable as the company continues to strengthen its financial and operational capabilities. Mr. Gilboa added that he is confident that Mr. Rubin’s financial leadership will bolster the company as its clinical programs progress.
Prior to joining Nasus Pharma, Mr. Rubin served as Chief Financial Officer and Senior Vice President of Protalix BioTherapeutics, Inc., where he led financial operations, strategy, and capital markets activities. He also served as Chief Financial Officer of BrainStorm Cell Therapeutics, Inc. and as Vice President and Head of Corporate Treasury at Teva Pharmaceutical Industries Ltd.
Mr. Rubin holds a BA in Business Management from the College of Management Academic Studies, Israel, and an MBA in Accounting and Finance from Bar-Ilan University, both summa cum laude.
Mr. Rubin said he believes the company’s innovative intranasal drug delivery platform and advancing clinical program represent a significant opportunity to bring innovative drug delivery products to patients and address unmet medical needs. He added that he looks forward to partnering with the leadership team to support the company’s continued progress and long-term growth.
Nasus Pharma is a clinical-stage pharmaceutical company developing intranasal powder products addressing acute medical conditions. Its lead product candidate, NS002, is an intranasal powder Epinephrine product candidate being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis.
Nasus Pharma’s proprietary powder-based intranasal (PBI) technology is designed for rapid and reliable drug delivery, utilizing the nasal cavity’s vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Nasus Pharma can be followed on Twitter (X) or Linkedin.
Investor Contact:
Arx Investor Relations
North American Equities Desk
nasus@arxhq.com
Source: Nasus Pharma
